Tech Company Financing Transactions
Myonexus Therapeutics Funding Round
Myonexus Therapeutics, operating out of New Albany, received $2.5 million from CincyTech, GFB Onlus and Jain Foundation.
Transaction Overview
Company Name
Announced On
12/14/2017
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Seed
Investors
Proceeds Purpose
The seed financing will enable Myonexus to initiate a systemic Phase 1/2a clinical trial of MYO-101, the company's gene therapy candidate for treating LGMD2E (beta-sarcoglycanopathy), in early 2018.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
8000 Walton Pkwy. 255
New Albany, OH 43054
USA
New Albany, OH 43054
USA
Phone
Website
Email Address
Overview
Myonexus Therapeutics is a clinical stage gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children's Hospital, a leader in muscular dystrophy gene therapy discovery and translational research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Triplett
Chief Financial Officer
Peter Kleinhenz
Chief Operating Officer
Bruce Halpryn
Chief Scientific Officer
Louise Rodino-Klapac
Browse more venture capital transactions:
Prev: 12/14/2017: Vayyar Imaging venture capital transaction
Next: 12/14/2017: OTA Insight venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs